Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands

Summary The reaction of the heterocyclic thiol derivatives, 2-mercapto-1-methylimidazole (SH-imi), 5-mercapto-1-methyltetrazole (SH-tet), 2-mercaptobenzothiazole (SH-ben) and 5-phenyl-1,3,4-oxadiazole-2-thiol (SH-oxa), with trimethylgallium (1:1) afforded the dimeric or tetrameric complexes [Me 2 Ga...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Investigational new drugs 2011-10, Vol.29 (5), p.932-944
Hauptverfasser: Gallego, Beatriz, Kaluđerović, Milena R., Kommera, Harish, Paschke, Reinhard, Hey-Hawkins, Evamarie, Remmerbach, Torsten W., Kaluđerović, Goran N., Gómez-Ruiz, Santiago
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 944
container_issue 5
container_start_page 932
container_title Investigational new drugs
container_volume 29
creator Gallego, Beatriz
Kaluđerović, Milena R.
Kommera, Harish
Paschke, Reinhard
Hey-Hawkins, Evamarie
Remmerbach, Torsten W.
Kaluđerović, Goran N.
Gómez-Ruiz, Santiago
description Summary The reaction of the heterocyclic thiol derivatives, 2-mercapto-1-methylimidazole (SH-imi), 5-mercapto-1-methyltetrazole (SH-tet), 2-mercaptobenzothiazole (SH-ben) and 5-phenyl-1,3,4-oxadiazole-2-thiol (SH-oxa), with trimethylgallium (1:1) afforded the dimeric or tetrameric complexes [Me 2 Ga(S-imi)] 2 ( 1 ), [Me 2 Ga(S-tet)] 2 ( 2 ), [Me 2 Ga(S-ben)] 2 ( 3 ) and [Me 2 Ga(S-oxa)] 4 ( 4 ), respectively. Molecular structures of 2 and 4 were determined by X-ray diffraction studies. The cytotoxicity of the gallium(III) complexes 1 – 4 was tested against human cell lines 8505C anaplastic thyroid cancer, A253 head and neck tumor, A549 lung carcinoma, A2780 ovarian cancer, DLD-1 colon carcinoma and compared with those of cisplatin and Ga(NO 3 ) 3 . Compound 4 seems to be slightly more active against 8505C, A253 and A2780 and substantially more active than all the other complexes against DLD-1, with an IC 50 value of 5.49 ± 0.16 µM, very close to that of cisplatin (5.14 ± 0.12 µM). Complexes 1 – 4 were less toxic on normal human fibroblasts (WWO70327) than on the investigated tumor cell lines and more selective to cancer cells than cisplatin. DNA laddering method showed that treatment of the DLD-1 cell line with IC 90 doses of 1 – 4 resulted in the induction of apoptosis. Compound 1 caused apoptosis by upregulation of caspases 2, 3 and 8. Since no activity of caspase 9 is observed, complex 1 is causing apoptosis triggered by an extrinsic pathway. DNA-interaction tests have been also carried out. Solutions of all the studied complexes have been treated with different concentrations of fish sperm DNA (FS-DNA). Modifications of the UV spectra which gave intrinsic binding constants of 3.03 × 10 5 , 4.44 × 10 5 , 3.02 × 10 6 and 5.56 × 10 5  M −1 for 1 – 4 were observed, however, no notable interaction with pBR322 plasmid DNA was detected.
doi_str_mv 10.1007/s10637-010-9449-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1439230777</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1439230777</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-b2c921406c8b817e3acdd2d0a0457f6795bf94f1678bbbb7b82a9707fb60230e3</originalsourceid><addsrcrecordid>eNp1kUFvFCEUx4mxsWv1A3gxJF5qIvqYYYfh2Ky2btLoRc8EGGaXhhlGYNLOx_Abl3WrMU3K5R3e7_2B90PoDYWPFIB_ShSamhOgQARjgrTP0IqueU2gYc1ztALacNIIwU_Ry5RuAKAWnL1ApxWwhrctW6HfmyWHHO6ccXn5gNUUphySS1iNHU557hYcepz3Fn_-dkG0Gzs37vAUw2RjdjYdutqRP3i2OapxNt6qiHfKezcP59vt9j02YZi8vSv4rct7vLfZxmAW450p2S54lQP2bldS0it00iuf7OuHeoZ-Xn75sflKrr9fbTcX18QwYJnoyoiKMmhMq1vKba1M11UdKGBr3jdcrHUvWF820OpyuG4rJTjwXjdQ1WDrM3R-zC2f-TXblOXgkrHeq9GGOUnKalFAznlB3z1Cb8Icx_I6SSmtaE1FKwpFj5SJIaVoezlFN6i4SAry4EsefcniSx58ybbMvH1InvVgu38TfwUVoDoCqbTGnY3_Xf1k6j2B5aHn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1112131989</pqid></control><display><type>article</type><title>Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Gallego, Beatriz ; Kaluđerović, Milena R. ; Kommera, Harish ; Paschke, Reinhard ; Hey-Hawkins, Evamarie ; Remmerbach, Torsten W. ; Kaluđerović, Goran N. ; Gómez-Ruiz, Santiago</creator><creatorcontrib>Gallego, Beatriz ; Kaluđerović, Milena R. ; Kommera, Harish ; Paschke, Reinhard ; Hey-Hawkins, Evamarie ; Remmerbach, Torsten W. ; Kaluđerović, Goran N. ; Gómez-Ruiz, Santiago</creatorcontrib><description>Summary The reaction of the heterocyclic thiol derivatives, 2-mercapto-1-methylimidazole (SH-imi), 5-mercapto-1-methyltetrazole (SH-tet), 2-mercaptobenzothiazole (SH-ben) and 5-phenyl-1,3,4-oxadiazole-2-thiol (SH-oxa), with trimethylgallium (1:1) afforded the dimeric or tetrameric complexes [Me 2 Ga(S-imi)] 2 ( 1 ), [Me 2 Ga(S-tet)] 2 ( 2 ), [Me 2 Ga(S-ben)] 2 ( 3 ) and [Me 2 Ga(S-oxa)] 4 ( 4 ), respectively. Molecular structures of 2 and 4 were determined by X-ray diffraction studies. The cytotoxicity of the gallium(III) complexes 1 – 4 was tested against human cell lines 8505C anaplastic thyroid cancer, A253 head and neck tumor, A549 lung carcinoma, A2780 ovarian cancer, DLD-1 colon carcinoma and compared with those of cisplatin and Ga(NO 3 ) 3 . Compound 4 seems to be slightly more active against 8505C, A253 and A2780 and substantially more active than all the other complexes against DLD-1, with an IC 50 value of 5.49 ± 0.16 µM, very close to that of cisplatin (5.14 ± 0.12 µM). Complexes 1 – 4 were less toxic on normal human fibroblasts (WWO70327) than on the investigated tumor cell lines and more selective to cancer cells than cisplatin. DNA laddering method showed that treatment of the DLD-1 cell line with IC 90 doses of 1 – 4 resulted in the induction of apoptosis. Compound 1 caused apoptosis by upregulation of caspases 2, 3 and 8. Since no activity of caspase 9 is observed, complex 1 is causing apoptosis triggered by an extrinsic pathway. DNA-interaction tests have been also carried out. Solutions of all the studied complexes have been treated with different concentrations of fish sperm DNA (FS-DNA). Modifications of the UV spectra which gave intrinsic binding constants of 3.03 × 10 5 , 4.44 × 10 5 , 3.02 × 10 6 and 5.56 × 10 5  M −1 for 1 – 4 were observed, however, no notable interaction with pBR322 plasmid DNA was detected.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1007/s10637-010-9449-8</identifier><identifier>PMID: 20467884</identifier><identifier>CODEN: INNDDK</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Apoptosis ; Apoptosis - drug effects ; Cancer therapies ; Caspases - metabolism ; Cell Line, Tumor ; Cell Survival - drug effects ; Chemotherapy ; Crystallography, X-Ray ; Cytotoxicity ; DNA - metabolism ; DNA Fragmentation - drug effects ; Drug Screening Assays, Antitumor ; Drugs ; Gallium - pharmacology ; Heterocyclic Compounds - chemical synthesis ; Heterocyclic Compounds - chemistry ; Heterocyclic Compounds - pharmacology ; Humans ; Inhibitory Concentration 50 ; Ligands ; Medicine ; Medicine &amp; Public Health ; Models, Molecular ; Nitrates ; Oncology ; Ovarian cancer ; Pharmacology ; Pharmacology/Toxicology ; Plasmids - genetics ; Preclinical Studies ; Spectrophotometry, Ultraviolet ; Studies ; Sulfhydryl Compounds - chemical synthesis ; Sulfhydryl Compounds - chemistry ; Sulfhydryl Compounds - pharmacology ; Thyroid cancer</subject><ispartof>Investigational new drugs, 2011-10, Vol.29 (5), p.932-944</ispartof><rights>Springer Science+Business Media, LLC 2010</rights><rights>Springer Science+Business Media, LLC 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-b2c921406c8b817e3acdd2d0a0457f6795bf94f1678bbbb7b82a9707fb60230e3</citedby><cites>FETCH-LOGICAL-c404t-b2c921406c8b817e3acdd2d0a0457f6795bf94f1678bbbb7b82a9707fb60230e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10637-010-9449-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10637-010-9449-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20467884$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gallego, Beatriz</creatorcontrib><creatorcontrib>Kaluđerović, Milena R.</creatorcontrib><creatorcontrib>Kommera, Harish</creatorcontrib><creatorcontrib>Paschke, Reinhard</creatorcontrib><creatorcontrib>Hey-Hawkins, Evamarie</creatorcontrib><creatorcontrib>Remmerbach, Torsten W.</creatorcontrib><creatorcontrib>Kaluđerović, Goran N.</creatorcontrib><creatorcontrib>Gómez-Ruiz, Santiago</creatorcontrib><title>Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><addtitle>Invest New Drugs</addtitle><description>Summary The reaction of the heterocyclic thiol derivatives, 2-mercapto-1-methylimidazole (SH-imi), 5-mercapto-1-methyltetrazole (SH-tet), 2-mercaptobenzothiazole (SH-ben) and 5-phenyl-1,3,4-oxadiazole-2-thiol (SH-oxa), with trimethylgallium (1:1) afforded the dimeric or tetrameric complexes [Me 2 Ga(S-imi)] 2 ( 1 ), [Me 2 Ga(S-tet)] 2 ( 2 ), [Me 2 Ga(S-ben)] 2 ( 3 ) and [Me 2 Ga(S-oxa)] 4 ( 4 ), respectively. Molecular structures of 2 and 4 were determined by X-ray diffraction studies. The cytotoxicity of the gallium(III) complexes 1 – 4 was tested against human cell lines 8505C anaplastic thyroid cancer, A253 head and neck tumor, A549 lung carcinoma, A2780 ovarian cancer, DLD-1 colon carcinoma and compared with those of cisplatin and Ga(NO 3 ) 3 . Compound 4 seems to be slightly more active against 8505C, A253 and A2780 and substantially more active than all the other complexes against DLD-1, with an IC 50 value of 5.49 ± 0.16 µM, very close to that of cisplatin (5.14 ± 0.12 µM). Complexes 1 – 4 were less toxic on normal human fibroblasts (WWO70327) than on the investigated tumor cell lines and more selective to cancer cells than cisplatin. DNA laddering method showed that treatment of the DLD-1 cell line with IC 90 doses of 1 – 4 resulted in the induction of apoptosis. Compound 1 caused apoptosis by upregulation of caspases 2, 3 and 8. Since no activity of caspase 9 is observed, complex 1 is causing apoptosis triggered by an extrinsic pathway. DNA-interaction tests have been also carried out. Solutions of all the studied complexes have been treated with different concentrations of fish sperm DNA (FS-DNA). Modifications of the UV spectra which gave intrinsic binding constants of 3.03 × 10 5 , 4.44 × 10 5 , 3.02 × 10 6 and 5.56 × 10 5  M −1 for 1 – 4 were observed, however, no notable interaction with pBR322 plasmid DNA was detected.</description><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Cancer therapies</subject><subject>Caspases - metabolism</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Chemotherapy</subject><subject>Crystallography, X-Ray</subject><subject>Cytotoxicity</subject><subject>DNA - metabolism</subject><subject>DNA Fragmentation - drug effects</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Drugs</subject><subject>Gallium - pharmacology</subject><subject>Heterocyclic Compounds - chemical synthesis</subject><subject>Heterocyclic Compounds - chemistry</subject><subject>Heterocyclic Compounds - pharmacology</subject><subject>Humans</subject><subject>Inhibitory Concentration 50</subject><subject>Ligands</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Models, Molecular</subject><subject>Nitrates</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Pharmacology</subject><subject>Pharmacology/Toxicology</subject><subject>Plasmids - genetics</subject><subject>Preclinical Studies</subject><subject>Spectrophotometry, Ultraviolet</subject><subject>Studies</subject><subject>Sulfhydryl Compounds - chemical synthesis</subject><subject>Sulfhydryl Compounds - chemistry</subject><subject>Sulfhydryl Compounds - pharmacology</subject><subject>Thyroid cancer</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUFvFCEUx4mxsWv1A3gxJF5qIvqYYYfh2Ky2btLoRc8EGGaXhhlGYNLOx_Abl3WrMU3K5R3e7_2B90PoDYWPFIB_ShSamhOgQARjgrTP0IqueU2gYc1ztALacNIIwU_Ry5RuAKAWnL1ApxWwhrctW6HfmyWHHO6ccXn5gNUUphySS1iNHU557hYcepz3Fn_-dkG0Gzs37vAUw2RjdjYdutqRP3i2OapxNt6qiHfKezcP59vt9j02YZi8vSv4rct7vLfZxmAW450p2S54lQP2bldS0it00iuf7OuHeoZ-Xn75sflKrr9fbTcX18QwYJnoyoiKMmhMq1vKba1M11UdKGBr3jdcrHUvWF820OpyuG4rJTjwXjdQ1WDrM3R-zC2f-TXblOXgkrHeq9GGOUnKalFAznlB3z1Cb8Icx_I6SSmtaE1FKwpFj5SJIaVoezlFN6i4SAry4EsefcniSx58ybbMvH1InvVgu38TfwUVoDoCqbTGnY3_Xf1k6j2B5aHn</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Gallego, Beatriz</creator><creator>Kaluđerović, Milena R.</creator><creator>Kommera, Harish</creator><creator>Paschke, Reinhard</creator><creator>Hey-Hawkins, Evamarie</creator><creator>Remmerbach, Torsten W.</creator><creator>Kaluđerović, Goran N.</creator><creator>Gómez-Ruiz, Santiago</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>M0C</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7TM</scope></search><sort><creationdate>20111001</creationdate><title>Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands</title><author>Gallego, Beatriz ; Kaluđerović, Milena R. ; Kommera, Harish ; Paschke, Reinhard ; Hey-Hawkins, Evamarie ; Remmerbach, Torsten W. ; Kaluđerović, Goran N. ; Gómez-Ruiz, Santiago</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-b2c921406c8b817e3acdd2d0a0457f6795bf94f1678bbbb7b82a9707fb60230e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Cancer therapies</topic><topic>Caspases - metabolism</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Chemotherapy</topic><topic>Crystallography, X-Ray</topic><topic>Cytotoxicity</topic><topic>DNA - metabolism</topic><topic>DNA Fragmentation - drug effects</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Drugs</topic><topic>Gallium - pharmacology</topic><topic>Heterocyclic Compounds - chemical synthesis</topic><topic>Heterocyclic Compounds - chemistry</topic><topic>Heterocyclic Compounds - pharmacology</topic><topic>Humans</topic><topic>Inhibitory Concentration 50</topic><topic>Ligands</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Models, Molecular</topic><topic>Nitrates</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Pharmacology</topic><topic>Pharmacology/Toxicology</topic><topic>Plasmids - genetics</topic><topic>Preclinical Studies</topic><topic>Spectrophotometry, Ultraviolet</topic><topic>Studies</topic><topic>Sulfhydryl Compounds - chemical synthesis</topic><topic>Sulfhydryl Compounds - chemistry</topic><topic>Sulfhydryl Compounds - pharmacology</topic><topic>Thyroid cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gallego, Beatriz</creatorcontrib><creatorcontrib>Kaluđerović, Milena R.</creatorcontrib><creatorcontrib>Kommera, Harish</creatorcontrib><creatorcontrib>Paschke, Reinhard</creatorcontrib><creatorcontrib>Hey-Hawkins, Evamarie</creatorcontrib><creatorcontrib>Remmerbach, Torsten W.</creatorcontrib><creatorcontrib>Kaluđerović, Goran N.</creatorcontrib><creatorcontrib>Gómez-Ruiz, Santiago</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Nucleic Acids Abstracts</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gallego, Beatriz</au><au>Kaluđerović, Milena R.</au><au>Kommera, Harish</au><au>Paschke, Reinhard</au><au>Hey-Hawkins, Evamarie</au><au>Remmerbach, Torsten W.</au><au>Kaluđerović, Goran N.</au><au>Gómez-Ruiz, Santiago</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands</atitle><jtitle>Investigational new drugs</jtitle><stitle>Invest New Drugs</stitle><addtitle>Invest New Drugs</addtitle><date>2011-10-01</date><risdate>2011</risdate><volume>29</volume><issue>5</issue><spage>932</spage><epage>944</epage><pages>932-944</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><coden>INNDDK</coden><abstract>Summary The reaction of the heterocyclic thiol derivatives, 2-mercapto-1-methylimidazole (SH-imi), 5-mercapto-1-methyltetrazole (SH-tet), 2-mercaptobenzothiazole (SH-ben) and 5-phenyl-1,3,4-oxadiazole-2-thiol (SH-oxa), with trimethylgallium (1:1) afforded the dimeric or tetrameric complexes [Me 2 Ga(S-imi)] 2 ( 1 ), [Me 2 Ga(S-tet)] 2 ( 2 ), [Me 2 Ga(S-ben)] 2 ( 3 ) and [Me 2 Ga(S-oxa)] 4 ( 4 ), respectively. Molecular structures of 2 and 4 were determined by X-ray diffraction studies. The cytotoxicity of the gallium(III) complexes 1 – 4 was tested against human cell lines 8505C anaplastic thyroid cancer, A253 head and neck tumor, A549 lung carcinoma, A2780 ovarian cancer, DLD-1 colon carcinoma and compared with those of cisplatin and Ga(NO 3 ) 3 . Compound 4 seems to be slightly more active against 8505C, A253 and A2780 and substantially more active than all the other complexes against DLD-1, with an IC 50 value of 5.49 ± 0.16 µM, very close to that of cisplatin (5.14 ± 0.12 µM). Complexes 1 – 4 were less toxic on normal human fibroblasts (WWO70327) than on the investigated tumor cell lines and more selective to cancer cells than cisplatin. DNA laddering method showed that treatment of the DLD-1 cell line with IC 90 doses of 1 – 4 resulted in the induction of apoptosis. Compound 1 caused apoptosis by upregulation of caspases 2, 3 and 8. Since no activity of caspase 9 is observed, complex 1 is causing apoptosis triggered by an extrinsic pathway. DNA-interaction tests have been also carried out. Solutions of all the studied complexes have been treated with different concentrations of fish sperm DNA (FS-DNA). Modifications of the UV spectra which gave intrinsic binding constants of 3.03 × 10 5 , 4.44 × 10 5 , 3.02 × 10 6 and 5.56 × 10 5  M −1 for 1 – 4 were observed, however, no notable interaction with pBR322 plasmid DNA was detected.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>20467884</pmid><doi>10.1007/s10637-010-9449-8</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-6997
ispartof Investigational new drugs, 2011-10, Vol.29 (5), p.932-944
issn 0167-6997
1573-0646
language eng
recordid cdi_proquest_miscellaneous_1439230777
source MEDLINE; SpringerLink Journals
subjects Apoptosis
Apoptosis - drug effects
Cancer therapies
Caspases - metabolism
Cell Line, Tumor
Cell Survival - drug effects
Chemotherapy
Crystallography, X-Ray
Cytotoxicity
DNA - metabolism
DNA Fragmentation - drug effects
Drug Screening Assays, Antitumor
Drugs
Gallium - pharmacology
Heterocyclic Compounds - chemical synthesis
Heterocyclic Compounds - chemistry
Heterocyclic Compounds - pharmacology
Humans
Inhibitory Concentration 50
Ligands
Medicine
Medicine & Public Health
Models, Molecular
Nitrates
Oncology
Ovarian cancer
Pharmacology
Pharmacology/Toxicology
Plasmids - genetics
Preclinical Studies
Spectrophotometry, Ultraviolet
Studies
Sulfhydryl Compounds - chemical synthesis
Sulfhydryl Compounds - chemistry
Sulfhydryl Compounds - pharmacology
Thyroid cancer
title Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T08%3A34%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytotoxicity,%20apoptosis%20and%20study%20of%20the%20DNA-binding%20properties%20of%20bi-%20and%20tetranuclear%20gallium(III)%20complexes%20with%20heterocyclic%20thiolato%20ligands&rft.jtitle=Investigational%20new%20drugs&rft.au=Gallego,%20Beatriz&rft.date=2011-10-01&rft.volume=29&rft.issue=5&rft.spage=932&rft.epage=944&rft.pages=932-944&rft.issn=0167-6997&rft.eissn=1573-0646&rft.coden=INNDDK&rft_id=info:doi/10.1007/s10637-010-9449-8&rft_dat=%3Cproquest_cross%3E1439230777%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1112131989&rft_id=info:pmid/20467884&rfr_iscdi=true